Nuclear medicine

China's Gathering Place for Innovative Medical Products: VBEF's 8th Future Healthcare Ecological Fair Will Be Held in Beijing Soon

Retrieved on: 
Wednesday, March 20, 2024
Research, Peking University, Health, Belt, Conference, Growth, Microbial metabolism, University, Synthetic biology, Elective surgery, School, AI, Biomaterials Science, VBEF, Outline of health sciences, National Health Commission, Exhibition, Ecosystem, Primary health care, Health technology, Convention center, Nuclear medicine, Belt and Road Initiative, Ophthalmology, Pharmaceutical industry

It will be held at the Beijing Beiren Yichuang International Convention and Exhibition Center from May 7th to 10th, 2024.

Key Points: 
  • It will be held at the Beijing Beiren Yichuang International Convention and Exhibition Center from May 7th to 10th, 2024.
  • The results interpret future trends to global medical innovators, demonstrate the linkage and cooperation between China's medical innovation technology and industry to the world, provide medical innovative products and solutions to the world, and demonstrate the true power of medical innovation.
  • In 2024, Vcbeat will upgrade the Future Medical Top 100 Conference held for seven consecutive years to the VBEF Future Healthcare Ecological Fair to help China's medical innovation industry accelerate the growth and promote a new medical innovation ecosystem.
  • Global medical industry practitioners are welcome to participate in the 8th VBEF Future Healthcare Ecological Fair in 2024.

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on: 
Tuesday, April 9, 2024
Curium, Civil service commission, Prostate cancer, Patient, PET, News, INN, Cancer, Prostate, European, European Commission, FDA, Nuclear medicine, Physician, PSMA, Food, Medical imaging

PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.

Key Points: 
  • PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.
  • In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.
  • It is the #1 utilized PSMA PET agent in the U.S. market.
  • The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

Retrieved on: 
Monday, April 8, 2024
Party, Partnership, Patient, PET, Acquisition, Radiopharmaceutical, MENA, SPECT, Nuclear medicine, Medical imaging

PARIS, April 08, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has entered into an agreement with Eczacıbaşı Holding and Bozlu Group for the acquisition of Eczacıbaşı-Monrol Nuclear Product Co. (Monrol), a dedicated specialist in nuclear medicine. The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) capabilities, and PET & SPECT nuclear medicine infrastructure, as well as facilitate the development of cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes.

Key Points: 
  • It will expand Curium’s PET footprint of 34 sites in Western Europe and Asia with the addition of 12 owned and partnered sites in Eastern Europe and MENA regions.
  • In addition, Eczacıbaşı-Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, will add significant scale to Curium’s vertically integrated production and distribution capabilities.
  • Eczacıbaşı Holding and Curium are fully committed to navigating through this process efficiently and expect to finalize the transaction in due course.
  • The Parties expect to be able to close this transaction once the customary regulatory approvals will have been obtained.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Monday, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

GE HealthCare and Hartford HealthCare Renew and Evolve 7-Year Collaboration to Advance Patient Care and Access in Connecticut

Retrieved on: 
Thursday, March 14, 2024
Technology, Hospitals, Health Technology, Other Health, Radiology, Health, Pharmaceutical, Data Management, Artificial Intelligence, Diagnosis, Deep learning, PET/CT, Head, Experiential learning, Algorithm, Longevity, MRI, X-ray, HHC, Anesthesia, OEC, Patient, Artificial intelligence, Acquisition, Mammography, Software, Critical care, GE HealthCare, Artifact, Multimedia, Nuclear medicine

The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.

Key Points: 
  • The Care Alliance strives to assist Hartford HealthCare in increasing access to innovation while decreasing the total cost of care for patients.
  • The collaboration will increase patients’ access to GE HealthCare’s most current imaging technology, and may provide shorter scan times, reduced waiting times for care, and enable clinicians to have greater accuracy in diagnostic assessments.
  • The agreement also includes GE HealthCare patient monitoring, anesthesia, maternal infant care and diagnostic cardiology technologies.
  • GE HealthCare and Hartford HealthCare will also execute build-in-place upgrades with some existing MRI, CT, PET/CT, and X-rays to refresh older systems with fewer construction costs and while minimizing waste, equipment downtime, and disruption to patient care.

BWXT Releases 2024 Sustainability Report

Retrieved on: 
Thursday, March 14, 2024
Aerospace, Manufacturing, Energy, Nuclear, Engineering, BWXT, Sustainability, Employment, Social responsibility, Nuclear medicine, CSR, BWX Technologies, Renewable energy

BWX Technologies, Inc. (NYSE: BWXT) has released its 2024 Sustainability Report, demonstrating the company’s role in good governance, environmental stewardship, the ongoing global clean-energy transition, global security, investment in the communities where we operate, and many other initiatives critical to corporate social responsibility (CSR) excellence.

Key Points: 
  • BWX Technologies, Inc. (NYSE: BWXT) has released its 2024 Sustainability Report, demonstrating the company’s role in good governance, environmental stewardship, the ongoing global clean-energy transition, global security, investment in the communities where we operate, and many other initiatives critical to corporate social responsibility (CSR) excellence.
  • “At BWXT, we are committed to the employment of nuclear technology to solve some of the world’s most important problems,” said Rex Geveden, BWXT’s president and chief executive officer.
  • “This year’s Sustainability Report showcases the strides we continue making to strengthen our duty as a responsible business, and it highlights our legacy of manufacturing safe, high-quality components and our position as an industry leader in new nuclear advances in clean, secure energy, nuclear medicine and environmental management.”

Highmark Health, AHN Announce Plans to Transform Allegheny General Hospital Campus

Retrieved on: 
Thursday, April 4, 2024
Magnet, Temperature, Conference, Health, Growth, Bed, Transplant, Caregiver, Patient, Allegheny Health Network, Allegheny General Hospital, AHN, City, Research, Trauma, IMP, Electrophysiology, MD, Operating, AGH, Investment, System, Hospital, Heart, CVI, Safety, Lighting, Nuclear medicine, DSM-IV codes, Nursing

PITTSBURGH, April 4, 2024 /PRNewswire-PRWeb/ -- Highmark Health and Allegheny Health Network (AHN) officials today reinforced a commitment to their Living Health model by announcing plans for continued significant investments in the network. Specifically, Allegheny General Hospital (AGH), AHN's flagship academic medical center, will be transformed with a new cardiovascular tower and emergency department, among other upgrades, further advancing and modernizing the hospital's care delivery and technological capabilities.

Key Points: 
  • PITTSBURGH, April 4, 2024 /PRNewswire-PRWeb/ -- Highmark Health and Allegheny Health Network (AHN) officials today reinforced a commitment to their Living Health model by announcing plans for continued significant investments in the network.
  • "Creating high-quality patient experiences and outcomes, and equitable access, through personalized care models designed to promote wellness and address health needs, is our goal at AHN.
  • The centerpiece of the AGH campus transformation is construction of a new patient tower which will house the nationally recognized services of the AHN Cardiovascular Institute (CVI).
  • One such project already underway at the hospital is the creation of a new hub for the AHN Neuroscience Institute.

Ratio Therapeutics Strengthens its Leadership Team with the Appointments of Bill Cupelo as Chief Business Officer and D. Scott Holbrook to its Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
College, Molecular imaging, Growth, Neurology, Data science, Nuclear medicine, Georgetown University, Patient, Business development, Regis College, Wheeling University, Radiopharmaceutical, GMP, Holy Cross, Therapy

"We are pleased to welcome Bill Cupelo and D. Scott Holbrook to the Ratio team," commented Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio.

Key Points: 
  • "We are pleased to welcome Bill Cupelo and D. Scott Holbrook to the Ratio team," commented Dr. Jack Hoppin, Chairman and Chief Executive Officer of Ratio.
  • "These appointments underscore our commitment to building a leadership team that will propel us forward in advancing our radiopharmaceutical platforms.
  • "I am honored to join Ratio at such a pivotal time, as the development of targeted radiopharmaceuticals continues to build momentum in our industry," said Bill Cupelo, Chief Business Officer of Ratio.
  • Previously, Mr. Cupelo also served as Vice President of Business Development and Strategic Accounts, and Software Product Manager at Invicro.